| 000 | 03073na a2200529 4500 | ||
|---|---|---|---|
| 999 |
_c1135 _d1135 |
||
| 003 | PC1135 | ||
| 005 | 20200310113710.0 | ||
| 008 | 130622s2013 xxx||||| |||| 00| 0 eng d | ||
| 040 | _cH12O | ||
| 041 | _aeng | ||
| 100 |
_aCarreira Delgado, Patricia Esmeralda _9467 _eReumatología |
||
| 245 | 0 | 0 |
_aClinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study. _h[artículo] |
| 260 |
_bClinical and experimental rheumatology, _c2013 |
||
| 300 | _a31(2 Suppl 76):96-102. | ||
| 500 | _aFormato Vancouver: Heijnen IA, Foocharoen C, Bannert B, Carreira PE, Caporali R, Smith V et al. Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study. Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):96-102. | ||
| 501 | _aPMID: 23101460 | ||
| 504 | _aContiene 34 referencias | ||
| 520 | _aOBJECTIVES: To determine the clinical characteristics of simultaneous occurrence of antitopoisomerase (ATA) and anticentromere (ACA) autoantibodies in systemic sclerosis (SSc). | ||
| 710 |
_9123 _aServicio de Reumatología |
||
| 856 |
_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc1135.pdf _ySolicitar documento |
||
| 942 |
_n0 _2ddc _cART |
||